Table 1.
Patients and Treatment Information
| Patient No. | Gender/age (y) | Cancer | pre-RT ICG-R15 |
post-RT ICG-R15 |
Total dose (Gy) |
Fraction Dose (Gy) |
|---|---|---|---|---|---|---|
| 1 | M/55 | HCC | 16.26 | 30.3 | 62 | 2 |
| 2 | M/65 | HCC | 23.2 | 27.53 | 50 | 10 |
| 3 | M/77 | Cholangiocarcinoma | 8.29 | 13.2 | 48 | 2 |
| 4 | M/54 | HCC | 48.1 | 48.7 | 50 | 10 |
| 5 | F/45 | Colorectal metastases | 13.4 | 14 | 63 | 3 |
| 6 | M/62 | Anal metastases | 11.5 | 16.6 | 52.5 | 2.5 |
| 7 | M/43 | HCC | 35 | 53.18 | 64 | 2 |
| 8 | M/58 | Colon metastases | 6.72 | NA | 82 | 2 |
| 9 | M/72 | Colon metastases | 19.79 | 21.98 | 75 | 3 |
| 10 | M/65 | HCC | 44.15 | 44.09 | 30 | 10 |
| 11 | M/80 | Neuroendocrine metastases | 9.63 | 21.33 | 55 | 2.5 |
| 12 | F/76 | Cholangiocarcinoma | 41.83 | 41.27 | 70 | 2 |
| 13 | M/72 | HCC | 13 | 22.31 | 50 | 2.5 |
| 14 | M/58 | HCC | 38.87 | 39.46 | 30 | 10 |
| 15 | F/74 | Cholangiocarcinoma | 9.93 | 13.81 | 48.4 | 2.2 |
| 16 | F/79 | HCC | 11.53 | 14.23 | 50 | 10 |
| 17 | F/51 | Rectal meatstases | 10.38 | NA | 55 | 11 |
| 18 | M/71 | HCC | 10.08 | 11.88 | 55 | 11 |
| 19 | M/56 | HCC | 27.94 | 31.98 | 48.6 | 11/7.8* |
| 20 | M/76 | HCC | 41.27 | 45.16 | 33 | 11 |
| 21 | M/81 | HCC | 51.69 | 64.73 | 22.8 | 7.6 |
| 22 | F/54 | HCC | 11.71 | 13.2 | 60 | 12 |
| 23 | M/60 | HCC | 13.6 | 14.2 | 60 | 12 |
R15: ICG retention rate 15 min after administration; HCC: hepatocellular carcinoma; NA: data not available;
*
First three fractions: 11Gy/fraction, remaining: 7.8Gy/fraction